Literature DB >> 23754304

Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.

Matthew A Kinseth1, Zhenyu Jia, Farahnaz Rahmatpanah, Anne Sawyers, Manuel Sutton, Jessica Wang-Rodriguez, Dan Mercola, Kathleen L McGuire.   

Abstract

In prostate cancer, race/ethnicity is the highest risk factor after adjusting for age. African Americans have more aggressive tumors at every clinical stage of the disease, resulting in poorer prognosis and increased mortality. A major barrier to identifying crucial gene activity differences is heterogeneity, including tissue composition variation intrinsic to the histology of prostate cancer. We hypothesized that differences in gene expression in specific tissue types would reveal mechanisms involved in the racial disparities of prostate cancer. We examined 17 pairs of arrays for AAs and Caucasians that were formed by closely matching the samples based on the known tissue type composition of the tumors. Using pair-wise t-test we found significantly altered gene expression between AAs and CAs. Independently, we performed multiple linear regression analyses to associate gene expression with race considering variation in percent tumor and stroma tissue. The majority of differentially expressed genes were associated with tumor-adjacent stroma rather than tumor tissue. Extracellular matrix, integrin family and signaling mediators of the epithelial-to-mesenchymal transition (EMT) pathways were all downregulated in stroma of AAs. Using MetaCore (GeneGo) analysis, we observed that 35% of significant (p < 10(-3)) pathways identified EMT and 25% identified immune response pathways especially for interleukins-2, -4, -5, -6, -7, -10, -13, -15 and -22 as the major changes. Our studies reveal that altered immune and EMT processes in tumor-adjacent stroma may be responsible for the aggressive nature of prostate cancer in AAs.
© 2013 UICC.

Entities:  

Keywords:  EMT; immune response; prostate cancer; racial disparity; stroma expression

Mesh:

Year:  2013        PMID: 23754304      PMCID: PMC3800217          DOI: 10.1002/ijc.28326

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Assessing gene significance from cDNA microarray expression data via mixed models.

Authors:  R D Wolfinger; G Gibson; E D Wolfinger; L Bennett; H Hamadeh; P Bushel; C Afshari; R S Paules
Journal:  J Comput Biol       Date:  2001       Impact factor: 1.479

3.  p53 Pro72Arg polymorphism and prostate cancer in men of African descent.

Authors:  L Ricks-Santi; T Mason; V Apprey; C Ahaghotu; A McLauchlin; D Josey; G Bonney; G M Dunston
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

Review 4.  Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?

Authors:  Patrick Micke; Arne Ostman
Journal:  Lung Cancer       Date:  2004-08       Impact factor: 5.705

5.  IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells.

Authors:  Angara Sureshbabu; Hiroshi Okajima; Daisuke Yamanaka; Elizabeth Tonner; Surya Shastri; Joanna Maycock; Malgorzata Szymanowska; John Shand; Shin-Ichiro Takahashi; James Beattie; Gordon Allan; David Flint
Journal:  J Cell Sci       Date:  2012-02-10       Impact factor: 5.285

6.  In silico estimates of tissue components in surgical samples based on expression profiling data.

Authors:  Yipeng Wang; Xiao-Qin Xia; Zhenyu Jia; Anne Sawyers; Huazhen Yao; Jessica Wang-Rodriquez; Dan Mercola; Michael McClelland
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

7.  Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.

Authors:  Michael J Callahan; Zoltan Nagymanyoki; Tomas Bonome; Michael E Johnson; Babak Litkouhi; Elizabeth H Sullivan; Michelle S Hirsch; Ursula A Matulonis; Joyce Liu; Michael J Birrer; Ross S Berkowitz; Samuel C Mok
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease.

Authors:  Eva LaTulippe; Jaya Satagopan; Alex Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

9.  Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.

Authors:  Olga A Timofeeva; Xueping Zhang; Habtom W Ressom; Rency S Varghese; Bhaskar V S Kallakury; Kan Wang; Youngmi Ji; Amrita Cheema; Mira Jung; Milton L Brown; Johng S Rhim; Anatoly Dritschilo
Journal:  Int J Oncol       Date:  2009-10       Impact factor: 5.650

10.  Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans.

Authors:  Carolina Bonilla; Stanley Hooker; Tshela Mason; Cathryn H Bock; Rick A Kittles
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

View more
  39 in total

1.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Authors:  Yongquan Wang; Jianghua Wang; Li Zhang; Omer Faruk Karatas; Longjiang Shao; Yiqun Zhang; Patricia Castro; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

Review 2.  Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?

Authors:  Berna C Özdemir; Gian-Paolo Dotto
Journal:  Trends Cancer       Date:  2017-03-06

3.  Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients.

Authors:  Hersh K Bhargava; Patrick Leo; Robin Elliott; Andrew Janowczyk; Jon Whitney; Sanjay Gupta; Pingfu Fu; Kosj Yamoah; Francesca Khani; Brian D Robinson; Timothy R Rebbeck; Michael Feldman; Priti Lal; Anant Madabhushi
Journal:  Clin Cancer Res       Date:  2020-03-05       Impact factor: 12.531

Review 4.  Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer.

Authors:  LaCreis R Kidd; K Sean Kimbro; Susan T Yeyeodu
Journal:  Cancer Immunol Res       Date:  2019-09       Impact factor: 11.151

Review 5.  Beyond the black box: a systematic review of breast, prostate, colorectal, and cervical screening among native and immigrant African-descent Caribbean populations.

Authors:  Nathan S Consedine; Natalie L Tuck; Camille R Ragin; Benjamin A Spencer
Journal:  J Immigr Minor Health       Date:  2015-06

Review 6.  Lung cancer health disparities.

Authors:  Bríd M Ryan
Journal:  Carcinogenesis       Date:  2018-05-28       Impact factor: 4.944

Review 7.  Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity.

Authors:  David P Turner
Journal:  Cancer Res       Date:  2015-04-28       Impact factor: 12.701

8.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.

Authors:  Richa Rai; Shalini S Yadav; Heng Pan; Irtaza Khan; James O'Connor; Mohammed Alshalalfa; Elai Davicioni; Emanuela Taioli; Olivier Elemento; Ashutosh K Tewari; Kamlesh K Yadav
Journal:  Cancer Rep (Hoboken)       Date:  2018-12-13

9.  Reclassification rates are higher among African American men than Caucasians on active surveillance.

Authors:  Debasish Sundi; Farzana A Faisal; Bruce J Trock; Patricia K Landis; Zhaoyong Feng; Ashley E Ross; H Ballentine Carter; Edward M Schaeffer
Journal:  Urology       Date:  2014-10-14       Impact factor: 2.649

10.  AGE metabolites: a biomarker linked to cancer disparity?

Authors:  Dion Foster; Laura Spruill; Katherine R Walter; Lourdes M Nogueira; Hleb Fedarovich; Ryan Y Turner; Mahtabuddin Ahmed; Judith D Salley; Marvella E Ford; Victoria J Findlay; David P Turner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-22       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.